Jury Hands Down $42.5M Total Verdict Against Philip Morris and RJR in Retrial Over Smoker’s Cancer Death – CVN News

Stock image.

Miami, FL R.J. Reynolds and Philip Morris were hit with a $42.5 million total verdict in a retrial over the 1996 cancer death of a Florida smoker. Gloger v. R.J. Reynolds and Philip Morris, 2011-CA-23377.

The award includes $15 million in compensatories awarded Friday, as well as an $11 million punitive award imposed against Philip Morris and $16.5 million in punitives imposed against Reynolds Wednesday for the responsibility jurors found the companies bore for Irene Glogers lung cancer.

Gloger, who had smoked for decades, died at 47, about a year after she quit smoking. Her family contends a tobacco industry-wide conspiracy to hide the dangers of smoking throughout much of the 20th century hooked Gloger to cigarettes and ultimately led to her fatal cancer.

The verdictmore than doubles the $17.5 million jurors awarded in a 2018, CVN-covered trial of the case. That verdict was thrown out in March by Floridas Third District Court of Appeal, which found the trial court had not not properly limited Kenneth Glogers testimony concerning conversations he had with his wifes doctors.

The Gloger case is among thousands that stem from Engle v. Liggett Group Inc., a 1994 Florida state court class-action lawsuit against Philip Morris and other tobacco companies. The state's supreme court ultimately decertified the class, but ruled that so-called Engle progeny cases may be tried individually. Plaintiffs are entitled to the benefit of the jury's findings in the original verdict, including the determination that tobacco companies placed a dangerous, addictive product on the market and conspired to hide the dangers of smoking.

However, in order to be entitled to those findings, plaintiffs must prove the smokers at the heart of their cases suffered from nicotine addiction that caused a smoking-related illness.

The origin of Glogers cancer, as well as what, if any responsibility she bore for her smoking, served as key battle lines in the 12-day trial.

During Fridays closings in the trials first phase, on Engle class membership, King & Spaldings Cory Hohnbaum, representing Reynolds, challenged the claim that Gloger had smoking-related lung cancer, and argued that a mass was never found in Glogers lung. He also contended doctors could not agree on the cell-type of Glogers cancer.

There is confusion, massive confusion among the pathologists about what this was, Hohnbaum said, noting Gloger saw several pathologists during her treatment. You dont need to go talk to multiple pathologists if the pathology is clear. It was never clear.

Arnold & Porters Keri Arnold, representing Philip Morris, added that, regardless of the cancers origin, Gloger knew the dangers of cigarettes, yet chose to continue smoking. Arnold noted that Gloger had been smoking for years by the time she began smoking Philip Morris brand cigarettes. She was an adult, she was married, she had a family, she was a medical professional. She had all the maturity and information she needed to make her own decisions about her own smoking and her own health, Arnold said.

But the Gloger familys attorney, The Ratzan Law Groups Stuart Ratzan, argued Gloger was heavily addicted to cigarettes and unable to stop in time to avoid her cancer. Ratzan walked jurors through Glogers smoking history, which included numerous failed quit attempts. Theres no reason no reason at all for a person to coat their lungs every 30 or 40 minutes, a pack-and-a-half a day for 30 years, if its not for nicotine, Ratzan said. Its the only reason.

And Ratzan argued medical records and pathology reports showed Glogers treating physicians concluded she had lung cancer. He noted one pathology report, on fluid taken from around Glogers lungs, found she had non-small cell carcinoma. It means lung cancer, Ratzan said. And I defy anybody to determine otherwise.

Email Arlin Crisco at acrisco@cvn.com.

Related Information

Watch the trial.

Not a subscriber?

Learn how you can watch blockbuster trials, in Florida and across the country.

See the rest here:
Jury Hands Down $42.5M Total Verdict Against Philip Morris and RJR in Retrial Over Smoker's Cancer Death - CVN News

Virtual Care-The road ahead in healthcare – BusinessLine

Virtual Care, is perhaps the next big wave in healthcare management that is emerging with the US targeting 2030 for realising some tangible applications.

Big data, Genomics, Personalised medicine, Stem Cell therapy and application of tools like Artificial Intelligence will drive dramatic developments in modern medicine that promise to tame many diseases, says David Hayes, Enterprise Medical Director (Provider Relations) , Mayo Clinic Network.

Virtual Care is the delivery of healthcare by harnessing the power of the Smart phone, Computer, tablet, apps etc. There are several efforts globally to develop platforms for reaching benefits of medicine to people, overcoming limitations of geography and physical presence.

At present the norm is Doctor will see you. In 2030, it could be the Patient is dialled in and wants to talk to the doctor, says Hayes. Virtual Care can bring down costs of treatment down in the long term. Patients too can derive benefits of home monitoring the treatment, he told BusinessLine in a recent interaction.

In several developed nations, efforts are on to create platforms so that quality healthcare is conveniently accessible to people wherever and whenever they need. The goal is to reach cost effective, timely treatment, which is reliable too. Virtual Care is mutually beneficial to patients and physicians. Working professionals or the elderly can get the care and medical advise from their homes, instead of a doctor's clinic or a huge corporate hospital visit.

Citing an example, Hayes said, Mayo Clinic, the 155 year old multi-billion dollar healthcare major headquartered in Minnesota, US is working with Google to establish a medical platform, which will see the large resource experts of Mayo and its associates globally linked to help patients. Similarly, Mayo Clinics, itself is utilising its medical expertise and providing tele-healthcare services.

Big data analysis and exploiting the potential of AI will significantly change the medicine of the near future. Drug development will be accelerated with the discovery, clinical trials and feedback become faster, said Hayes, who was in Hyderabad to jointly announce that AIG Hospitals will be the first Indian healthcare group to join the worldwide Mayo Clinic Network.

How reliable is tele-health? This question is important in countries like India, given the infrastructure and other bottlenecks as well as developed countries too. In 2019, the American Medical Association (AMA) has come up with guideline for physicians to ensure quality in delivering Virtual Care. According to reports, the US is projected to face a shortage of a lakh doctors by 2030, which pushes up pressure in healthcare delivery by increasing wait time for patients

Hayes, a noted Cardiologist with contributions in implantable cardiac devices feels, the huge expertise that India has developed in medicine can be leveraged in the development of the cost-effective, efficient systems for Virtual Care as well as in emerging technologies.

Asked about developments in ICDs that can make heart treatment still better, Hayes said Implantable devices have hit a peak. There can at best be incremental improvements. The future is machine to machine communication. More machine based treatments (Robotics) that can improve the quality of care.

See the article here:
Virtual Care-The road ahead in healthcare - BusinessLine

Cell Harvesting Systems Market: Key Players and Production Information analysis – Global Banking And Finance Review

Cell harvesting is a technique of collecting stem cells for regenerate, transplant or repair the damaged organ with healthy functioning ones.Cell harvestingis considered as an important step in biopharmaceutical manufacturing industry that can directly affect the product quality and related downstream processes. Stem cells harvesting helps in treating with diseases namely cancers, blood disorders, immune deficiency diseases and various injuries. This therapy is also beneficial for burn victims which help them in grafting new skin cells as a replacement for damaged ones.

Many companies are focusing on regeneration of myocardial tissue by injection of cell graft consist of adult stem cells from the patients for manufacturing regenerating medicines. For the treatment of eye diseases new healthy cells are also be grown. For harvesting bone marrow a companies are manufacturing devices with passive flexible drilling unit and suction mechanism which will help in reducing the invasiveness of bone marrow transplantation. Cell harvesting system helps in reducing the invasiveness of bone marrow aspiration from the iliac bone with less punctures. Moreover, helps in reducing procedure time and contamination by T-cells.

Request to Sample of Report @https://www.futuremarketinsights.com/reports/sample/rep-gb-1754

Global Banking & Finance Jobs

Cell Harvesting Systems Market:Drivers and Restraints : Cell Harvesting Systems Market are witnessing maximum growth owing to increase bone marrow transplantation procedures attributed to high prevalence of blood cancer and anemia. Moreover, improving healthcare expenditure, survival rate after treatment, increasing investment in logistic services, expansion bone marrow transplant registry for heart along with neuronal disorders and growing per capita healthcare expenditure. However, high cost of cumbersome treatment, lack of reimbursement policies, immunological rejection, viable cell density, and identification of stem cells in adult tissues, and complications during cell harvesting and inadequate number of HSCs cells for transplantation is a major barrier to the cell harvesting systems market.

Cell Harvesting Systems Market:Segmentation : The cell harvesting systems market has been classified on the basis of techniques, application and end user. Based on techniques, the cell harvesting systems market is segmented into the following: Altered Nuclear Transfer, Blastomere Extraction Based on application, the cell harvesting systems market is segmented into the following: Bone Marrow, Peripheral Blood, Umbilical Cord Blood, Adipose Tissue, Based on end-user, the cell harvesting systems market is segmented into the following: Research Centers, Academics Institutes, Diagnostic Labs, Hospitals

Download Table of [emailprotected]https://www.futuremarketinsights.com/toc/rep-gb-1754

Cell Harvesting Systems Market:Overview :Cell harvesting systems market witnessed substantial growth owing to equipment efficacy and accuracy during stem cells harvest. By application type, bone marrow aspiration is anticipated to hold the major share in the cell harvesting systems market owing to less process error, safe and simple procedure and less side effects. People suffering from Leukemia eligible for bone marrow transplant, is expected to contribute highest share in the global cell harvesting systems market. Cell harvesting systems helps in enhancing proper pigmentation in scar reconstruction which encourage companies for continuous technology advancement in both cell isolation techniques and downstream purification processes.

Cell Harvesting Systems Market: Region-wise Outlook : Depending on geographic region, cell harvesting systems marketis segmented into seven key regions: North America, Latin America, Eastern Europe, Western Europe, Asia Pacific, Japan, and Middle East & Africa. Asia Pacific dominates the cell harvesting systems marketfollowed by Europe, Japan and North America owing to high concentration of bone marrow stem cells harvesting centers and registries along with skilled doctors for the process of harvesting stem cells in these regions. Asia Pacific, Middle East and Africa hold huge potential and shows substantial growth in terms of wide acceptance of new technologyowing to awareness among population, increasing healthcare expenditure along with high number of potential candidate for the procedure.

Request for [emailprotected]https://www.futuremarketinsights.com/customization-available/rep-gb-1754

Cell Harvesting Systems Market:Key Players :Key players of cell harvesting systems market are PerkinElmer Inc. Tomtec, Bertin Technologies, TERUMO BCT, INC., hynoDent AG, Avita Medical, Argos Technologies, Inc., SP Scienceware, Teleflex Incorporated., Arthrex, Inc., Thomas Scientific, BRAND GMBH

Continued here:
Cell Harvesting Systems Market: Key Players and Production Information analysis - Global Banking And Finance Review

There is No Cure for Type 1 Diabetes. You Can Change That. – 5280 | The Denver Magazine

Paid for and Posted by Children's Diabetes Foundation

More than 30 million Americans, or roughly 9.4% of your friends, neighbors, coworkers, or family members are living with diabetes, which means you probably know someone with the disease. But do you know what life with diabetes actually looks like? Or that there are multiple types with big differences?

November is Diabetes Awareness Month, so all month long theChildrens Diabetes Foundationis debunking the myths abouttype 1 diabetes.

The facts may surprise you

Approximately 1.25 million Americans have type 1 diabetes, an autoimmune disease, which means the person did nothing to cause their diagnosis. Their body stopped producing insulin, which regulates the amount of sugar in the blood. Many type 1s rely on Continuous Glucose Monitors (CGMs) and insulin pumps or frequent injections to maintain the delicate balancing act your body performs naturally.

The exact cause of the disease is still unknown, but research at the Barbara Davis Center here in Denver, supported by the Childrens Diabetes Foundation is looking for answers. Some factors may be genetic, or some may be environmental. As we learn more, we get one step closer to finding a cure.

Type 1 diabetes used to be called childhood or juvenile diabetes. This changed years ago because doctors and researchers have learned that a diagnosis can happen at any age, from infants to seniors. Fifty percent of people diagnosed today are over 18 years old.

There is no cure yet for type 1 diabetes. Researchers continue to do stem cell research in hopes of finding a cure for the millions of people living with type 1 diabetes. But as a chronic autoimmune disease, we know its not something that can be cured by a change in diet or new exercise regimen.

And sometimes they need to eat or drink something sugary to stay alive. When blood sugars are too low, a type 1 must eat something to raise their blood sugar to avoid going unconscious, having a seizure, or even death.

Be on the lookout for these symptoms:

Wear a blue shirt this November, the color of diabetes awareness, to help us spread the word. When someone asks you about it, share what youve learned here and invite them to visitChildrensDiabetesFoundation.org to learn more. The more we know and talk about type 1 diabetes, the better allies we can all be in this fight.

The Childrens Diabetes Foundation is the fundraising arm of theBarbara Davis Center (BDC), one of the largest type 1 diabetes centers in the world. Donations directly support the BDC clinics, research, and programs. No one is turned away for care at the BDC. In fact, 40% of patients are uninsured or underinsured. The Childrens Diabetes Foundation also has programs for education and awareness, support groups, financial support for type 1 families, an Advocate program, and more.

With Colorado Gives Day just around the corner on December 10th, we would love to have your support. Schedule your donation today atColoradoGives.org/CDF.

Original post:
There is No Cure for Type 1 Diabetes. You Can Change That. - 5280 | The Denver Magazine

Heartbreaking moment dad meets the woman who saved his life – he feared his son would grow up without a father – Manchester Evening News

This is the tear-jerking moment a dad shares a hug with the woman who saved his life.

James O'Donnell, from Burnage, feared the worst after being diagnosed with a blood disorder similar to leukaemia in 2016.

Usual treatments were failing and James was undergoing a blood transfusion every week while battling constant infections, the Liverpool Echo reports.

James was running out of options and despaired at the pain his death could cause his eight-year-old son, Harrison.

But in a stunning stroke of fortune, his saviour was only the other side of the M62 - LiverpoolCouncil admin worker Leah McDougall.

The 29-year-old mum, from Bootle, had taken the time to sign up to the register of potential stem cell donors on her lunch break at a pop-up stall, organised by blood cancer charity DKSM, the previous year.

James, who despite his Manc heritage is an avid Liverpool FC fan, told staff at the charity that he would be up for meeting his donor, who could have been anyone from a number of European countries using the register.

James, along with his wife Andrea and young Harrison, got the chance to meet Leah for the first time at a DKSM charity gala in London on Wednesday last week (November 6).

James, who says he finally feels like himself after a long period of illness, told the ECHO: "I was just getting chest infections and water infections all the time.

"I am quite a healthy person, and I was in good shape and I knew I should not be getting ill all the time."

He said after a few weeks of tests his was invited to take a bone marrow biopsy and was told the devastating news on his 40th birthday.

The disease meant James' bone marrow was not producing enough white blood cells, but doctors told him a treatment called anti-thymocite globulin (ATG) had a "75% chance" of success.

However, when that failed, fear and doubt began to creep in.

He said: "We are always saying I would get through this, we were thinking I would get better. But I started to think it's not happening, it's not going to be for me, this.

"I thought, I have been good in life, I need some luck. We were having a really hard time.

"My son was four or five then, and it was hard for him having a dad going from playing football with him to being in hospital."

Eventually doctors revealed the only option was for James to have a bone marrow transplant.

The O'Donnell's went through further disappointment when tests on his three siblings revealed none were a match, so the waiting game to find a suitable donor began.

But on a March day in 2017, he got a call to say: "We have got a perfect match, a 10 out of 10."

The operation was a success and after four weeks doctors told James the new bone marrow cells were taking effect.

He said: "We were so lucky to find a donor only about 25 miles away. Some people never find one and we had one on our doorstep."

The powerful emotion of meeting Leah last week is summed up by James: "It was the second best moment of my life after my son being born.

"What she has done means that I can see my son growing up and that he has a father."

Leah did not hesitate to agree to help a total stranger when she was asked by DKSM.

Describing the moment she met James and his family, she told the ECHO: "We were both speechless. When I walked on stage we were just hugging each other for ages.

"It is weird, we felt like we had known each other for years, I felt like I had known him my whole life.

"It just takes five minutes out of your time to sign up to the register; that's like going to the kitchen to make a drink.

"You just think about the impact it is going to have on someone, it is saving someone's life. I feel lucky to have been able to give something back."

James says his family and Leah are planning to meet up again, possibly at a Liverpool FC game.

He said: "Without her, I wouldn't have a future."

DKSM has urged anyone aged 17-55, and in general good health, to sign up to the register here.

Dr Manos Niklolousis, Haematologist at University Hospital Birmingham NHS Foundation Trust, said:"Blood stem cells can be used to treat a wide range of blood cancers and blood disorders and we urgently need more people to come forward as donors.

"Currently, only 2% of the UK population are registered so matching donors with patients isnt easy within a growing multicultural population.

"Many of those in need are unable to find a sibling match and so rely on the generosity of strangers, and a blood stem cell transplant can be some patients only hope of survival.

"As a doctor who treats people with blood cancer or disorders, it is upsetting to know that some patients could have been saved if only more potential donors were registered and available to donate.

"I look forward to the day when there will be a donor for every patient in need."

Excerpt from:
Heartbreaking moment dad meets the woman who saved his life - he feared his son would grow up without a father - Manchester Evening News

Discover the Global Cord Stem Cell banking Market gain impetus due to the growing demand over 2026 – Markets Gazette 24

Global Cord Stem Cell Banking Market By Storage Type (Private Banking, Public Banking), Product Type (Cord Blood, Cord Blood & Cord Tissue), Service Type (Collection & Transportation, Processing, Analysis, Storage), Source (Umbilical Cord Blood, Bone Marrow, Peripheral Blood Stem, Menstrual Blood), Indication (Cerebral Palsy, Thalassemia, Leukemia, Diabetes, Autism), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Industry Trends and Forecast to 2026

Market Analysis: Global Cord Stem Cell Banking Market

Global Cord stem cell banking market is estimated to reach USD 13.8 billion by 2026 registering a healthy CAGR of 22.4%. The increasing number of parents storing their childs cord blood, acceptance of stem cell therapeutics, high applicability of stem cells are key driver to the market.

Market Definition: Global Cord Stem Cell Banking Market

Cord stem cells banking is nothing but the storing of the cord blood cell contained in the umbilical cord and placenta of a newborn child. This cord blood contains the stem cells which can be used in future to treat disease such as leukemia, thalassemia, autoimmune diseases, and inherited metabolic disorders, and few others.

Market Drivers

Market Restraint

Get Sample Analysis of Global Market Information: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cord-stem-cell-banking-market

Segmentation: Global Cord Stem Cell Banking Market

By Storage Type

By Product Type

By Service Type

By Indication

By Source

By Geography

Key Developments in the Market:

Get TOC of Full Report: https://www.databridgemarketresearch.com/toc/?dbmr=global-cord-stem-cell-banking-market

Competitive Analysis: Global Cord Stem Cell Banking Market

Global cord stem cell banking market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions and others to increase their footprints in this market. The report includes market shares of cord stem cell banking market for Global, Europe, North America, Asia Pacific, South America and Middle East & Africa.

Key Market Competitors: Global Cord Stem Cell Banking Market

Few of the major market competitors currently working in the global cord stem cell banking market are CBR Systems, Inc., Cordlife, Cells4Life Group LLP, Cryo-Cell International, Inc., Cryo-Save AG, Lifecell, StemCyte India Therapeutics Pvt. Ltd, Viacord, SMART CELLS PLUS., Cryoviva India, Global Cord Blood Corporation, National Cord Blood Program, Vita 34, ReeLabs Pvt. Ltd., Regrow Biosciences Pvt. Ltd. , ACROBiosystems., Americord Registry LLC., New York Blood Center, Maze Cord Blood, GoodCell., AABB, Stem Cell Cryobank, New England Cryogenic Center, Inc. among others

Research Methodology:Global Cord Stem Cell Banking Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more pleaseRequest an Analyst Callor can drop down your inquiry.

The key research methodology used byDBMR Researchteam is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Primary Respondents

Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.

Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Reasons to Purchase this Report

Customization of the Report:

To Know More : https://www.databridgemarketresearch.com/reports/global-cord-stem-cell-banking-market

About Us

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. GetCustomizationandDiscounton Report by emailingCorporatesales@databridgemarketresearch.com. We are content with our glorious 99.9 % client satisfying rate.

Contact Us

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475Mail:Corporatesales@databridgemarketresearch.comhttps://databridgemarketresearch.com

See more here:
Discover the Global Cord Stem Cell banking Market gain impetus due to the growing demand over 2026 - Markets Gazette 24

Innovation Pharmaceuticals: Oral Cancer on the Rise; Company Offers Perspectives on Opportunity of Brilacidin for the Prevention of Oral Mucositis -…

BEVERLY, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (the Company), a clinical stage pharmaceutical company, is pleased to provide perspectives on the unmet patient need in OM and global commercial opportunity of Brilacidin, the Companys defensin-mimetic drug candidate, for the prevention of Severe Oral Mucositis (SOM) in Head and Neck Cancer (HNC) patients receiving chemoradiation.

Quite simply, OM is a significant unmet patient need in supportive cancer care, with a sizable commercial opportunity attached to delivering novel OM therapies, said Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticals. We believe that Brilacidin, as a result of our promising Phase 2 results showing a marked reduction in the incidence of SOM, further advantaged by a patient-friendly oral rinse formulation conveniently packaged in sachet form, leads the competitive field of OM drugs in development. Negotiations with potential pharmaceutical partners interested in licensing our Brilacidin for OM asset continue, with the Company remaining diligent as it works toward executing the next step in the drug candidates development.

Over 500,000 Annual Cases of SOM Globally by 2025 and No Drugs on Market Today

Millions of patients worldwide suffer from OM, a costly and debilitating side-effect of chemoradiation, with the majority of therapies currently in use consisting of medical devices that are palliative in nature and poorly reimbursed. OM is particularly common in HNC, affecting each year approximately 65,000, 150,000, and 300,000 patients respectively in the U.S., Europe and Asia. Worldwide, by 2025, annual new HNC cases are expected to approach 930,000. Almost all HNC patients will develop some form of OM, with ~70 percent developing SOM. Patients with SOM are more likely to experience treatment-limiting and even life-threatening interruptions in their chemoradiation regimens. Additional costs incurred due to SOM range from $18,000 to over $42,000 per case on average.

Rising Rates of Oral Cancer

While the incidence of many cancers is decreasing, oral cancer is on the rise. According to the Oral Cancer Foundation, about 657,000 cases of oral or oropharyngeal cancer (including the larynx) are reported annually worldwide. Common causes are the sexually transmitted HPV, smoking and alcohol consumption. The Centers for Disease Control and Prevention estimate that 7 out of every 10 oropharyngeal cancers are caused by HPV. About 43 percent of patients with oral cavity cancer die within five years.

Large Void, Up to $2.5 Billion Global Annual Market Opportunity

Various pharmaceutical companies are conducting clinical trials in an attempt to bring OM drugs to market. One company, Galera Therapeutics, an OM-focused pharma, raised $150 million in October 2018, and recently completed a $60 million IPO, to fund the development of its OM drug candidate. A safe and effective drug to preventor even reduce the duration of SOMhas the potential to fill a large void in supportive cancer care and capture a substantial new market, an annual global commercial opportunity estimated to range between $500 million and $2.5 billion.

Compelling Economics, Attractive Marketing Dynamic

The Company estimates relatively low Cost-of-Goods to produce Brilacidin oral rinse per course of treatment, thereby creating favorable economics to price the product competitively and still generate healthy margins. Palifermin (Kepivance), the only approved drug to treat OM (in Hematopoietic Stem Cell Transplantation), was priced at $8,250 upon product launch in 2005, and currently is priced at approximately $16,000. ProGrow Pharma Partners estimates the market price for novel OM drugs to be between $9,000 (Europe) and $18,000 (U.S.). By eliminating the considerable associated patient costs attributable to OM, surveys of payers in the U.S. have indicated a willingness to pay up to $20,000 for a preventative OM treatment.

Currently, about 2,500 facilities in the U.S. treat HNC patients undergoing chemoradiation regimens. As a subset, approximately 60 percent of all HNC patients are treated in just 500 of these facilities. A small salesforce could thus be deployed to detail physicians and other care professionals treating a majority of HNC patients. This marketing dynamic further lends to the attractive economics for the development of a drug in this category of medical need.

About Brilacidin Phase 2 Oral Mucositis Trial

The Companys Brilacidin oral rinse for OM demonstrated a strong therapeutic benefit in HNC patients receiving the aggressive chemotherapy regimen (cisplatin administered 80-100 mg/m2, every 21 days), which currently is in common use. In this patient population, incidence of SOM (WHO Grade 3) was reduced to 25.0 percent in the modified Intent-to-Treat (mITT) population, versus 71.4 percent in the placebo patient group. In the Per Protocol (PP) patient group, incidence of SOM dropped to 14.3 percent for patients receiving Brilacidin, compared to 72.7 percent among those receiving placebo.

The completed Phase 2 study (see NCT02324335) met its primary endpoint, showing a reduction of SOM incidence versus placebo, as well as beneficial treatment effects in reducing the duration of SOM and in delaying the onset of SOM. Furthermore, Brilacidin showed a favorable safety profile and was well-tolerated.

About Brilacidin and Severe Oral Mucositis

There currently are no FDA-approved drugs for the prevention of Severe OM (SOM) (WHO Grade 3) in HNC patients receiving chemoradiation. The additional expenses incurred by patients suffering from SOM are estimated to be as high as $18,000 to over $42,000 per case in the U.S. when hospitalization is required. These factors contribute to SOM qualifying as an area of significant unmet medical need. According to published statistics, the number of new annual HNC cases in the U.S. is estimated to be 65,000, and worldwide, ~750,000 cases. Approximately 70 percent of HNC patients receiving chemoradiation typically will develop Severe OM, with the overall incidence of HNC patients developing some grade of OM (WHO Grades 1 to 4) approaching 100 percent. Because it cannot be predicted which patients will develop SOM, a preventative treatment, such as Brilacidin oral rinse, would begin in all patients as soon as starting chemoradiation and continue until its completion (typically a seven-week course). Given Brilacidin is administered as a convenient oral rinse, with plans to package it in an easily transportable sachet form, the Company believes it would be attractive both to doctors and patientslikely translating to widespread and rapid market adoption should Brilacidin oral rinse gain regulatory approval.

AlertsSign-up for Innovation Pharmaceuticals email alerts is available at:http://www.ipharminc.com/email-alerts/

About Innovation PharmaceuticalsInnovation Pharmaceuticals Inc. (IPIX) is a clinical stage biopharmaceutical company developing a world-class portfolio of innovative therapies addressing multiple areas of unmet medical need, including inflammatory diseases, cancer, infectious disease, and dermatologic diseases.Brilacidin, a versatile compound with broad therapeutic potential, is in a new chemical class called defensin-mimetics.A Phase 2 trial of Brilacidin as an oral rinse for the prevention of Severe Oral Mucositis (SOM) in patients with Head and Neck Cancer, met its primary and secondary endpoints, including reducing the incidence of SOM.The Company plans to advance Brilacidin oral rinse into Phase 3 development, subject to available financial resources. Positive results were also observed in a Phase 2 Proof-of-Concept trial treating patients locally with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS).Brilacidin for UP/UPS was licensed to Alfasigma S.p.A. in July 2019. A Phase 2b trial of Brilacidin showed a single intravenous dose of the drug delivered comparable outcomes to a seven-day dosing regimen of the FDA-approved blockbuster daptomycin in treating Acute Bacterial Skin and Skin Structure Infection. Kevetrin is a novel anti-cancer drug shown to modulate p53, often referred to as the Guardian Angel Gene due to its crucial role in controlling cell mutations and has successfully completed a Phase 2 trial in Ovarian Cancer.More information is available on the Company website atwww.IPharmInc.com.

Forward-Looking Statements: This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 including statements concerning the future execution of a definitive agreement with a global pharmaceutical company and the anticipated terms thereof, our future drug development plans, other statements regarding future product developments, and markets, including with respect to specific indications, and any other statements which are other than statements of historical fact. These statements involve risks, uncertainties and assumptions that could cause the Companys actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. The Company has in some cases identified forward-looking statements by using words such as anticipates, believes, hopes, estimates, looks, expects, plans, intends, goal, potential, may, suggest, and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are the Companys need for, and the availability of, substantial capital in the future to fund its operations and research and development; the Companys licensee(s) may not successfully complete pre-clinical or clinical testing and the Company will not receive milestone payments; or the Companys compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in the Companys filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. The Company undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

INVESTOR AND MEDIA CONTACTInnovation Pharmaceuticals Inc.Leo Ehrlichinfo@ipharminc.com

Read more:
Innovation Pharmaceuticals: Oral Cancer on the Rise; Company Offers Perspectives on Opportunity of Brilacidin for the Prevention of Oral Mucositis -...

South Shields cancer survivor bursts into tears as she finally meets the woman who saved her life – Chronicle Live

A cancer survivor has finally met her anonymous saviour almost a decade after her transplant.

Becca Anderson, from South Shields, was diagnosed with leukaemia ten years ago.

As a student aged 18, Becca often felt ill but thought it merely was the result of stress and working too hard, but blood tests confirmed something far more serious.

The 28-year-old said: Id been poorly for a few months and I was actually on my way to a party when I got the phone call from my dad.

"Id had a blood test and the doctor rang the house phone trying to reach me but because of how serious it was, they told him to call me and get me to the hospital straight away."

At Sunderland Royal Hospital accompanied with her boyfriend and her mum, doctors informed Becca she had leukaemia.

"I just remember saying, 'Im going to die. Im going to die', she said.

"I calmed down but there were a lot of tears, it was dramatic."

Due to the high chance of relapse, Becca was told she would need a stem cell transplant if she were to be cured of her cancer.

Without a match within her family, the charity Anthony Nolan searched the stem cell register. Fortunately, a match was found soon after.

On November 2010, Becca went into hospital where she had her transplant and remained in isolation for two months.

Speaking of her journey to recovery, Becca said: "Its only really been the last two or three years that Ive fully got my confidence back. Everyones journey will be different, but recovery is hard."

Her donor was Susan Fullerton, from Glasgow, who joined the Anthony Nolan stem cell register on April 2010 after losing her mum to acute myeloid leukaemia in 2003.

Susan, 38, said: "I could remember how much blood transfusions gave my mum almost immediate colour and energy, so I decided to become a blood donor.

"At one of my donation sessions there were leaflets on the table about Anthony Nolan, so I decided to sign up."

Anthony Nolan gives people with blood cancer a second chance of life by finding them matching donors.

It also carries out ground-breaking research to save more lives and provide information to support patients after a stem cell transplant.

Lifesavers like Susan have a 1 in 800 chance of being called up to donate in the following five years. However, Susan was found to be a match just weeks after joining the register.

Both Beccas and Susans identity was kept secret from each other for two years as per the charitys procedure.

After the period passed, they were both allowed to meet each other. In September, nine years after surgery, both of them almost by chance decided to reach out to the charity within a few days of each other.

Becca, now a cabin crew member for Virgin Atlantic, was planning to do the Great North Run for Anthony Nolan and thought it would be the perfect timing for her to meet the stranger who saved her life.

Susan on the other hand wanted to share her story to encourage people to join the stem cell register due to her friends young child currently being treated for leukaemia.

When she decided to reach out she was surprised Becca wanted to do the same.

"It was no-brainer, I felt like I was missing part of my story, said Susan.

Becca said: "It was so overwhelming as it happened so quickly. Meeting my donor was a pipe dream and next thing I knew she was coming to Newcastle."

When they finally met at Central Station a day before the Great North Run, they hugged each other and burst into tears.

Speaking of their meeting, Becca said: "Meeting her was like meeting a friend. It was like a strange blind date that you just knew was going to work out."

Susan also felt a connection and said: "It never felt like I didnt know her. It just felt like I had known her my whole life, maybe it was because she had a piece of me inside her."

Becca and Susan plan to stay in touch and will meet each others families next month.

Looking back, Becca said: "Without Anthony Nolan and Susan, I genuinely wouldnt be here. I now see so many people not getting matches and I just think, 'wow, how lucky was I?'

"Looking back, I was so naive at the time. I never thought I wouldnt find a match."

Find out more about the work of Anthony Nolan at http://www.anthonynolan.org

See the rest here:
South Shields cancer survivor bursts into tears as she finally meets the woman who saved her life - Chronicle Live